Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Last trade$249.28
Day change-$2.37 (-0.94%)
Day range$247.03 – $259.04
Volume397,749
Market cap$37.20B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.2B
Price / earnings
107.05×
Price / book
1.97×
Price / sales
3.61×
EV / sales
4.23×
EV / EBITDA
22.58×
Profitability
Earnings per share
$2.35
Return on assets
1.08%
Return on equity
1.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.41×
Current ratio
1.95×
Quick ratio
1.37×
Cash ratio
0.33×
Cash flow
Price / cash flow
16.55×
Price / free cash flow
17.96×
Free cash flow
$2.07B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BIIB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.8B
$2.74B
$2.48B
$2.28B
$2.53B
$2.65B
$2.43B
$2.45B
Cost of revenue
$748.4M
$776.9M
$661M
$495.5M
$674.4M
$605M
$629.3M
$583.5M
Gross profit
$2.06B
$1.96B
$1.82B
$1.78B
$1.86B
$2.04B
$1.8B
$1.87B
Selling, general and administrative
$752M
$709.7M
$607.3M
$682.5M
$594.8M
$583.8M
$572.5M
$680M
Research and development
$857.8M
$693.6M
$573M
$731.8M
$438.2M
$445.6M
$634.8M
$532.3M
Total operating expenses
$1.93B
$1.81B
$1.42B
$1.69B
$1.26B
$1.25B
$1.42B
$1.43B
Operating income
$128.8M
$150.9M
$397.4M
$98.4M
$597M
$792.7M
$379.6M
$441.4M
Interest expense
$0
-$82.3M
$0
$0
$0
-$72.6M
$0
$0
Income before taxes
-$9M
$132.4M
$377.7M
-$56M
$557.3M
$744M
$311.2M
$291.5M
Income taxes
$11.6M
$34.9M
$58.2M
-$7.1M
$90.8M
$109.2M
$70.7M
$24.8M
Net income
-$20.6M
$97.5M
$319.5M
-$48.9M
$466.5M
$634.8M
$240.5M
$266.7M
Net income attributable to common shareholders
-$20.6M
$97.5M
$319.5M
-$48.9M
$466.5M
$634.8M
$240.5M
$266.7M
EBITDA
$436.4M
$554.9M
$609.7M
$329.7M
$806.6M
$999.5M
$598.1M
$606.9M
Basic earnings per share
-$0.14
$0.66
$2.17
-$0.33
$3.18
$4.33
$1.65
$1.83
Diluted earnings per share
-$0.14
$0.66
$2.15
-$0.33
$3.17
$4.33
$1.64
$1.83
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Eisai and Biogen announced five-year data from the Clarity AD trial showing lecanemab (LEQEMBI) reduced relative risk of disease progression by 36% compared to natural history data. Over 60% of patients with low tau showed improvement or stability in cognitive function and daily living activities at five years, with benefits continuing to accrue over time. The safety profile remained consistent with no new findings observed.
State Street's XPH (SPDR S&P Pharmaceuticals ETF) is recommended over Invesco's PBE (Biotechnology & Genome ETF) for long-term investors due to its lower expense ratio (0.35% vs 0.59%), broader diversification with 61 holdings, lower beta, and better recent 1-year performance (38.6% vs 33.2%). While PBE offers a higher dividend yield (1.3% vs 0.4%), XPH's exposure to pharmaceutical acquisitions and lower costs make it more suitable for most long-term investors.
First Trust's FBT and Invesco's PBE are compared as primary vehicles for biotech sector exposure. FBT offers lower fees (0.55% vs 0.59%), higher AUM ($3.0B vs $438M), and stronger 1-year returns (35.7% vs 28.1%), while PBE provides dividend income and uses a multi-factor quantitative approach. The choice depends on investor priorities regarding cost, liquidity, and investment strategy.
Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.